Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.54 |
| ▸ | PLAT | P00750 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125689 | 0.89 | LMNA (0.65) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL265529 | 0.86 | LMNA (0.48) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL135662 | 0.86 | LMNA (0.48) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL135660 | 0.86 | LMNA (0.48) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL6913949 | 0.84 | LMNA (0.46) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL6908741 | 0.84 | LMNA (0.46) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL6914968 | 0.84 | LMNA (0.46) | PLGPLATLMNAANPEPENPEP | |
| Hydrochloric Acid SCHEMBL134213 | 0.84 | LMNA (0.46) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL6916906 | 0.84 | LMNA (0.46) | PLGPLATLMNAANPEPENPEP | |
| SCHEMBL9820825 | 0.84 | TSHR (0.52) | PLGPLATLMNAANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-9422475-B2 | Optically anisotropic compound and resin composition comprising the same | LG CHEM, LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
| US-8883952-B2 | Optically anisotropic compound and resin composition comprising the same | LG CHEM, LTD. (KR) | 2014-11-11 | — | — | US | disclosed |
| US-8163359-B2 | Retardation film, and polarizing plate and liquid crystal display comprising the same | LG CHEM, LTD. (KR) | 2012-04-24 | — | — | US | disclosed |
| US-20100137484-A1 | OPTICALLY ANISOTROPIC COMPOUND AND RESIN COMPOSITION COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
| US-20100105816-A1 | OPTICALLY ANISOTROPIC COMPOUND AND RESIN COMPOSITION COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20090169774-A1 | Retardation film, and polarizing plate and liquid crystal display comprising the same | LG CHEM, LTD. (KR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105816-A1 | OPTICALLY ANISOTROPIC COMPOUND AND RESIN COMPOSITION COMPRISING THE SAME | RER1, SEM1, RCC1 | PLG 3536/4885PLAT 2892/4885LMNA 3215/4885 |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | PLG 4808/4885PLAT 3731/4885LMNA 4194/4885 |
| US-20100137484-A1 | OPTICALLY ANISOTROPIC COMPOUND AND RESIN COMPOSITION COMPRISING THE SAME | RER1, RCC1, ALG3 | PLG 2306/4885PLAT 1365/4885LMNA 3270/4885 |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | PLG 4808/4885PLAT 3731/4885LMNA 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.